3 Marijuana Stocks Primed to Go From Zero to Hero

Small-cap weed companies The Supreme Cannabis Company, Inc. (TSX:FIRE), Neptune Wellness Solutions Inc. (TSX:NEPT)(NASDAQ:NEPT), and The Green Organic Dutchman Holdings Inc. (TSX:TGOD) are about to upstage the larger cannabis producers.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Investors’ interest is shifting from large-cap to small-cap cannabis companies. Because of the controversies and scandals involving the industry leaders, investors are now focusing on unheralded marijuana stocks that have the potential to go from zero to hero.

Supreme (TSX:FIRE), Neptune (TSX:NEPT)(NASDAQ:NEPT), and TGOD (TSX:TGOD) are finally getting attention. For those who are interested in investing in the cannabis space, all three companies are becoming alternative options.

On fire

FIRE is regaining strength after losing some of its thrust in mid-June. The company received a solid boost after sealing an agreement to acquire Truverra. Supreme will control two subsidiaries: Canadian Clinical Cannabinoids Inc. and Truverra Europe B.V. It’s like hitting two birds with one stone.

This strategic acquisition means Supreme can significantly boost its presence in the Canadian and European markets. The facilities of Canadian Clinical will be used to produce top-quality cannabis extracts, and Supreme can use the same facilities to produce concentrates and vaping liquids.

Supreme will have even more assets when the company completes the acquisition of the multi-licensed BlissCo Cannabis. Investors, take note: Supreme is not interested in a market share of low-dollar cannabis strains. The company will concentrate on the premium products markets where its brand is already known. Expect FIRE to sizzle in the months ahead.

Nutraceuticals to cannabis

Neptune is one of the biggest gainers in the cannabis sector. So far this year, it has grown 101.7%, proving that the decision of management to shift from nutraceuticals to cannabis was a smart one. The company’s expertise in extraction and purification will be the key to gaining headway in the fast-growing industry.

Neptune signed an agreement to provide Canopy Growth with extraction and purification services. The volume requirement is huge, so Neptune will be generating profit from this allied business. Two more extraction agreements were signed with cannabis companies Tilray and TGOD.

Health Canada also granted Neptune a cannabis-processing licence, so the company can start shipping extracts from its Quebec facility. Because Neptune has acquired the North Carolina-based cannabis supplier Sugarleaf, the company expects to generate $150 million in revenue from U.S. markets over the next three years.

Captured market

There’s more incentive for investors to take TGOD seriously from now on. Health Canada has renewed the licences of the company’s Ancaster, Ontario, facility until August 2022, giving TGOD the authority to cultivate, process, and sell cannabis from this site.

Further, the state-of-the-art hybrid greenhouse at Ancaster is nearing completion. From late August, TGOD will be able to ramp up production and execute the company’s business plan. The 166,000-square-foot facility will produce 17,500 kilograms annually. TGOD is also eyeing global exports.

In fact, TGOD is positioning itself to become the world’s premium organic cannabis company. Its operations are geared towards the medical cannabis markets in Canada, Europe, Latin America, and the Caribbean. TGOD will also be active in the Canadian adult-use market.

In Canada, its competitive advantage lies in its organic hemp CBD oil operations. TGOD grows high-quality, certified, organic cannabis, and medical patients can benefit from hemp’s sustainable, all-natural principles. TGOD plans to cultivate up to 219,000 kilograms in processing facilities in three countries.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks